The global market for Klinefelter syndrome therapeutics is projected to grow from USD 1.14 billion in 2023 to USD 1.85 billion by 2033, with a compound annual growth rate (CAGR) of 5%. This growth is driven by an increase in the prevalence of Klinefelter syndrome, advancements in therapeutics, and growing awareness. Klinefelter syndrome, the most common chromosomal disorder in males, affects 1 in every 500 to 1,000 male births in the United States, with a rising number of diagnosed cases globally. North America leads the market, accounting for nearly 38% of the global market share by 2033. Europe is the second fastest-growing region, expected to command a 34% market share by the end of the forecast period. Asia Pacific is projected to grow at a CAGR of 5.1% through 2033, making it the fastest-growing region in the Klinefelter syndrome therapeutics market.